2008-Apr-22 | Archemix’ ARC1779 Granted Orphan Designation for the Treatment of TTP, a Life-Threatening Blood Disorder... More

2008-Mar-17 | Archemix Announces Initiation of Phase 2 Trial for Aptamer Product Candidate ARC1779 in Patients with TTP, a Rare, Life-Threatening Blood Disorder... More

2008-Mar-13 | Archemix CEO to Present at the 28th Annual Cowen and Company Health Care Conference... More